Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab

Breast Cancer

Volumn 23, Issue 4, 2016, Pages 624-632

  Shimizu, Chikako ^a,b   Mogushi, Kaoru ^b   Morioka, Masaki Suimye ^b   Yamamoto, Harukaze ^a   Tamura, Kenji ^a   Fujiwara, Yasuhiro ^a   Tanaka, Hiroshi ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Fc gamma receptor polymorphism; Gene set enrichment analysis; HER2 positive breast cancer; Peripheral blood mononuclear cell; Trastuzumab

Indexed keywords

ARGININE; FC RECEPTOR IIA; FC RECEPTOR IIIA; HISTIDINE; IMMUNOGLOBULIN RECEPTOR; PHENYLALANINE; TRASTUZUMAB; UNCLASSIFIED DRUG; VALINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FC RECEPTOR; FCGR3A PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; FCGRIIA GENE; FCGRIIIA GENE; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HER2 POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LOADING DRUG DOSE; MALE; METASTASIS; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; BREAST NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, IGG; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84929179747     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-015-0614-y     Document Type: Article

References (25)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/new oncogene. Science. 1987;235:177–82.
2. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in Breast Cancer. Clin Cancer Res. 2012;19:28–33.
3. Woof JM, Burton DR. Human antibody-Fc receptor interaction illuminated by crystal structures. Nat Rev Immunol. 2004;4:89–99.
4. Bournazos S, Woof JF, Hart SP, Dransfield I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol. 2009;157:244–54.
5. Armour KL, Van de Winkel JGJ, Willamson LM, Clark MR. Differential binding to human Fc gamma IIA and Fc gamma IIB receptors by human IgG wild type and mutant antibodies. Mol Immunol. 2003;40:58–593.
6. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90:1109.
7. Carson WE, Parihar R, Lindeman MJ, Personeni N, Dierksheide J, Meropol NJ, et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated HER2/new-positive breast cancer cells. Eur J Immnol. 2001;31:3016–25.
8. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, et al. FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol. 2011;22:1302–7.
9. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26:1789–96.
10. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, et al. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012;18:3467–86.
11. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hemat Oncol. 2013;6(1):8722–6.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
13. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–9.
14. www.broadinstitute.org.gsea. Accessed 13 July 2011.
15. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamtsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002;87:21–7.
16. Tichatchek E, Zielinski CC, Muller C, Sevelda P, Kubista E, Czerwenka K, et al. Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer. Cancer Immunol Immunother. 1988;27:278–82.
17. Wang Y, Wang S, Ding Y, Ye Y, Xu Y, He H, et al. A suppressor of cytokine signaling 1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived dendritic cells. Clin Vaccine Immunol. 2013;20:1449–56.
18. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19:1858–72.
19. Benson DM, Calguiri MA. Killer immunoglobulin-like receptors and tumor immunity.Cancer. Immunol Res. 2014;2:99–104.
20. Bakema JE, van Egmond M. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr Top Microbiol Immunol. 2014;382:373–92.
21. Albanesi M, Mancardi DA, Jonsson F, Iannascoli B, Fiette L, Si Santo JP, et al. Neutophils mediate antibody-induced antitumor effects in mice. Blood. 2013;122:3160–4.
22. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94:259–67.
23. Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, et al. Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): results from the FinHER trial. J Clin Oncol 2012; 30 (suppl.; abstr 507).
24. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132:793–805.
25. Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment GroupN9831 adjuvant trastuzumab trial. J Clin Oncol. 2015 (e-pub ahead of print).